We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genetic Test Indicates a Young Man's Chances of Becoming Bald

By Labmedica staff writers
Posted on 24 Jan 2008
A simple consumer-friendly test has been developed that provides an accurate and understandable genetic analysis of a man's likelihood of developing male pattern baldness (androgenetic alopecia).

A man can learn about his genetic predisposition to balding before he reaches the age of 40. More...
People who have certain variations in their X-chromosome are likely (95.1-98.1%) to develop pattern baldness before age 40. The test is simple--the man swabs his mouth (inside cheek) for several seconds and returns the swab to lab. The test is performed anonymously and the results delivered via a secure and private Web site.

The information provided by the test, which has been named HairDX, enables the consumer to make informed decisions about what approach, if any, he should take, including discussing hair loss with a qualified physician. HairDX.com also provides a support center with access to a registered nurse.

HairDX (Irvine, CA, USA) developed the genetic baldness test and has announced its commercial release. The company was founded by scientists and specialists in genetic analysis and hair therapies. It is created to help people make the right decisions about hair care, treatment, and restoration by providing accurate and accessible personalized scientific information.

The genetic analysis is performed by BioServe (Beltsville, MD, USA), a laboratory specializing in the processing, development, and validation of diagnostic tests for the practice of personalized, predictive, and preventive medicine. BioServe is a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory.

"The most common form of hair loss, androgenetic alopecia, is hereditary. Looking at your father's or grandfather's head has been an inaccurate, nonscientific barometer. The genetic revolution will enable patients and physicians to gain deeper understanding of hair loss,” said Peter Novak, M.D., Ph.D., a scientist at the University of Massachusetts Medical Center (Worcester, MA, USA). Dr Novak is an innovator in the field of stem cell therapies for treatment of hair loss.

"Each year, men in their 20s and 30s spend millions of dollars on pharmaceuticals, topical products, and other costly treatments trying to prevent baldness. Some of this is done by males who may not go bald in the first place,” said HairDX CEO Andy Goren.


Related Links:
HairDX
BioServe
University of Massachusetts Medical Center

Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Wound Irrigation Solution
Prontosan®
Monitor/Defibrillator
Zenix
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Artificial intelligence (AI) standalone performance and reader performance with versus without AI assistance. (A) Receiver operating characteristics (ROC) curve for AI standalone performance in the US dataset (AUC 0.899, 95% CI 0.858 to 0.939). (B) ROC curve for AI standalone performance in the Korean dataset (AUC 0.963, 95% CI 0.946 to 0.975). (C) Pooled reader ROC without (AUC 0.718) versus with (AUC 0.852) AI assistance in the Korean dataset; P<0.001. AUC, area under the receiver operating characteristics curve. (Leonard Sunwoo et al., Journal of NeuroInterventional Surgery (2026). DOI: 10.1136/jnis-2026-025339)

AI Improves Non-Contrast CT Interpretation for Time-Sensitive Stroke Assessment

Acute ischemic stroke occurs when a blood vessel in the brain becomes blocked, requiring rapid diagnosis to enable timely reperfusion therapy. Emergency departments often use computed tomography angiography... Read more

Critical Care

view channel
Image Credit: Adobe Stock

Noninvasive Imaging Approach Aims to Detect Basal Cell Carcinoma Before It Becomes Visible

Basal cell carcinoma is the most common form of skin cancer and can damage nearby structures such as the nose or eyes when it develops on the face. Diagnosis typically depends on visible skin changes,... Read more

Surgical Techniques

view channel
Image: Associate Professor Menglin Chen studies how the light-sensitive nanoparticles affect living cells. The screen shows calcium being released inside a cell after nanoparticles taken up by the cell are exposed to blue light. Calcium plays an important role in cellular signaling, and the experiment helps the researchers understand how the nanoparticles can translate light into biological activity. (Photo courtesy of Aarhus University, Johanne Holm Jensen)

Light-Activated Nanoparticles May Offer New Approach to Retinal Prostheses

Retinitis pigmentosa is a degenerative retinal disorder in which photoreceptors progressively die, reducing visual signals to the brain while leaving surviving inner retinal circuits underused.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.